Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

S.C. Vaz; J.A. Adam; R.C.D. Bolton; P. Vera; W. Van Elmpt; K. Herrmann; R.J. Hicks; Y. Lievens; A. Santos; H. Schoder; B. Dubray; D. Visvikis; E.G.C. Troost; L.F. De Geus-Oei

doi:10.1007/s00259-021-05624-5

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

S.C. Vaz, J.A. Adam, R.C.D. Bolton, P. Vera, W. Van Elmpt, K. Herrmann^*, R.J. Hicks, Y. Lievens, A. Santos, H. Schoder, B. Dubray, D. Visvikis, E.G.C. Troost, L.F. De Geus-Oei

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Purpose 2-[F-18]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[F-18]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

Original language	English
Pages (from-to)	1386-1406
Number of pages	21
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	49
Issue number	4
Early online date	13 Jan 2022
DOIs	https://doi.org/10.1007/s00259-021-05624-5
Publication status	Published - Mar 2022

Keywords

Radiotherapy
EANM
SNMMI
ESTRO
2-[F-18]FDG PET
CT
Radiation therapy
Planning
Lung cancer
POSITRON-EMISSION-TOMOGRAPHY
TARGET VOLUME DEFINITION
BODY RADIOTHERAPY SBRT
FDG-PET
TUMOR VOLUME
IMAGES
SEGMENTATION
GUIDELINES
ALGORITHM
THERAPY

Access to Document

10.1007/s00259-021-05624-5Licence: CC BY

1 Erratum / corrigendum / retractions

Correction to: Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0
Vaz, S. C., Adam, J. A., Bolton, R. C. D., Vera, P., van Elmpt, W., Herrmann, K., Hicks, R. J., Lievens, Y., Santos, A., Schöder, H., Dubray, B., Visvikis, D., Troost, E. G. C. & de Geus-Oei, L.-F., Jul 2022, In: European Journal of Nuclear Medicine and Molecular Imaging. 49, 9, p. 3300-3301 2 p.
Research output: Contribution to journal › Erratum / corrigendum / retractions › Academic

Open Access

Cite this

Vaz, S. C., Adam, J. A., Bolton, R. C. D., Vera, P., Van Elmpt, W., Herrmann, K., Hicks, R. J., Lievens, Y., Santos, A., Schoder, H., Dubray, B., Visvikis, D., Troost, E. G. C., & De Geus-Oei, L. F. (2022). Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. European Journal of Nuclear Medicine and Molecular Imaging, 49(4), 1386-1406. https://doi.org/10.1007/s00259-021-05624-5

@article{180edcef5058422599f9a49deb9abe81,

title = "Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0",

abstract = "Purpose 2-[F-18]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[F-18]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.",

keywords = "Radiotherapy, EANM, SNMMI, ESTRO, 2-[F-18]FDG PET, CT, Radiation therapy, Planning, Lung cancer, POSITRON-EMISSION-TOMOGRAPHY, TARGET VOLUME DEFINITION, BODY RADIOTHERAPY SBRT, FDG-PET, TUMOR VOLUME, IMAGES, SEGMENTATION, GUIDELINES, ALGORITHM, THERAPY",

author = "S.C. Vaz and J.A. Adam and R.C.D. Bolton and P. Vera and {Van Elmpt}, W. and K. Herrmann and R.J. Hicks and Y. Lievens and A. Santos and H. Schoder and B. Dubray and D. Visvikis and E.G.C. Troost and {De Geus-Oei}, L.F.",

note = "Funding Information: Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work. Funding Information: This guideline was brought to the attention of the relevant EANM Committees and the National Societies of Nuclear Medicine. The comments and suggestions from the EANM Dosimetry and Radiation Protection Committees, the SNMMI, and ESTRO-ACROP were highly appreciated and have been considered for this guideline. Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2022",

month = mar,

doi = "10.1007/s00259-021-05624-5",

language = "English",

volume = "49",

pages = "1386--1406",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer Verlag",

number = "4",

}

Vaz, SC, Adam, JA, Bolton, RCD, Vera, P, Van Elmpt, W, Herrmann, K, Hicks, RJ, Lievens, Y, Santos, A, Schoder, H, Dubray, B, Visvikis, D, Troost, EGC & De Geus-Oei, LF 2022, 'Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0', European Journal of Nuclear Medicine and Molecular Imaging, vol. 49, no. 4, pp. 1386-1406. https://doi.org/10.1007/s00259-021-05624-5

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. / Vaz, S.C.; Adam, J.A.; Bolton, R.C.D. et al.
In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 49, No. 4, 03.2022, p. 1386-1406.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

AU - Vaz, S.C.

AU - Adam, J.A.

AU - Bolton, R.C.D.

AU - Vera, P.

AU - Van Elmpt, W.

AU - Herrmann, K.

AU - Hicks, R.J.

AU - Lievens, Y.

AU - Santos, A.

AU - Schoder, H.

AU - Dubray, B.

AU - Visvikis, D.

AU - Troost, E.G.C.

AU - De Geus-Oei, L.F.

N1 - Funding Information: Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, and personal fees from Pharma15, outside the submitted work. Funding Information: This guideline was brought to the attention of the relevant EANM Committees and the National Societies of Nuclear Medicine. The comments and suggestions from the EANM Dosimetry and Radiation Protection Committees, the SNMMI, and ESTRO-ACROP were highly appreciated and have been considered for this guideline. Publisher Copyright: © 2022, The Author(s).

PY - 2022/3

Y1 - 2022/3

N2 - Purpose 2-[F-18]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[F-18]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

AB - Purpose 2-[F-18]FDG PET/CT is of utmost importance for radiation treatment (RT) planning and response monitoring in lung cancer patients, in both non-small and small cell lung cancer (NSCLC and SCLC). This topic has been addressed in guidelines composed by experts within the field of radiation oncology. However, up to present, there is no procedural guideline on this subject, with involvement of the nuclear medicine societies. Methods A literature review was performed, followed by a discussion between a multidisciplinary team of experts in the different fields involved in the RT planning of lung cancer, in order to guide clinical management. The project was led by experts of the two nuclear medicine societies (EANM and SNMMI) and radiation oncology (ESTRO). Results and conclusion This guideline results from a joint and dynamic collaboration between the relevant disciplines for this topic. It provides a worldwide, state of the art, and multidisciplinary guide to 2-[F-18]FDG PET/CT RT planning in NSCLC and SCLC. These practical recommendations describe applicable updates for existing clinical practices, highlight potential flaws, and provide solutions to overcome these as well. Finally, the recent developments considered for future application are also reviewed.

KW - Radiotherapy

KW - EANM

KW - SNMMI

KW - ESTRO

KW - 2-[F-18]FDG PET

KW - CT

KW - Radiation therapy

KW - Planning

KW - Lung cancer

KW - POSITRON-EMISSION-TOMOGRAPHY

KW - TARGET VOLUME DEFINITION

KW - BODY RADIOTHERAPY SBRT

KW - FDG-PET

KW - TUMOR VOLUME

KW - IMAGES

KW - SEGMENTATION

KW - GUIDELINES

KW - ALGORITHM

KW - THERAPY

U2 - 10.1007/s00259-021-05624-5

DO - 10.1007/s00259-021-05624-5

M3 - Article

C2 - 35022844

SN - 1619-7070

VL - 49

SP - 1386

EP - 1406

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 4

ER -

Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[F-18]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Abstract

Keywords

Access to Document

Fingerprint

Research output

Correction to: Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[18F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0

Cite this